Table 3.

Treatment Related Adverse Events

Adverse Event	Level 1 (N=3)				Level 2 (N=12)				Level 3 (N=3)				Total (N=18) N (%)
	Cycle 1	All Cycles			Cycle 1	All Cycles			Cycle 1	All Cycles
	Grade ≥3	Grade 1/2	Grade 3/4	Total N (%)	Grade ≥3	Grade 1/2	Grade 3/4	Total N (%)	Grade ≥3	Grade 1/2	Grade 3/4	Total N (%)
Abdominal infection	0	0	0	0	1	0	1	1 (8)	0	0	0	0	1 (6)
Anemia	0	0	0	0	1	1	1	2 (17)	0	1	0	1 (33)	3 (17)
Anorexia	0	2	0	2 (67)	0	7	1	8 (67)	1	2	1	3 (100)	13 (72)
Blurred vision	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Cheilitis	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Constipation	0	2	0	2 (67)	0	7	0	7 (58)	0	1	0	1 (33)	10 (56)
Diarrhea	0	0	0	0	1	3	1	4 (33)	0	0	0	0	4 (22)
Dizziness	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Dysgeusia	0	1	0	1 (33)	0	1	0	1 (8)	0	1	0	1 (33)	3 (17)
Dyspepsia	0	0	0	0	0	1	0	1 (8)	0	1	0	1 (33)	2 (11)
Edema	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Fatigue	0	1	0	1 (33)	1	6	2	8 (67)	2	0	2	2 (67)	11 (61)
Fever	0	0	0	0	0	2	0	2 (17)	0	0	0	0	2 (11)
Flushing	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Headache	0	1	0	1 (33)	0	3	0	3 (25)	0	1	0	1 (33)	5 (28)
Hyperglycemia	0	0	0	0	0	0	1	1 (8)	0	0	0	0	1 (6)
Hypomagnesemia	0	0	0	0	1	0	1	1 (8)	0	0	0	0	1 (6)
Insomnia	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Lymphocyte count decreased	0	0	0	0	1	0	1	1 (8)	0	0	0	0	1 (6)
Mucosal infection	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Myalgia	0	0	0	0	0	1	0	1 (8)	0	0	0	0	1 (6)
Nausea	0	3	0	3 (100)	0	9	0	9 (75)	1	2	1	3 (100)	15 (83)
Neutrophil count decreased	0	0	0	0	1	0	3	3 (25)	0	0	2	2 (67)	5 (28)
Platelet count decreased	0	1	0	1 (33)	0	3	0	3 (25)	0	0	1	1 (33)	5 (28)
Vomiting	0	1	0	1 (33)	0	2	0	2 (17)	0	2	0	2 (67)	5 (28)
Weight loss	0	0	0	0	0	2	0	2 (17)	0	2	0	2 (67)	4 (22)
White blood cell decreased	0	0	0	0	1	0	2	2 (17)	0	0	0	0	2 (11)